Sanofi-Aventis Will Enter U.S. OTC Market By Paying $1.9 Billion For Chattem

The deal, which is Sanofi's latest attempt to diversity in the face of a looming patent cliff, provides a platform for Rx-to-OTC switches.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet